Nelum Pharma

Nelum Pharma is a private, pre-revenue biotech focused on fibrosis and oncology. Its core asset is NLM-001, a potentially best-in-class hedgehog inhibitor in-licensed from Takeda (formerly TAK-441), which has demonstrated a favorable safety and pharmacokinetic profile in early clinical trials involving 60 patients. The company is led by a team of serial entrepreneurs and supported by a distinguished scientific advisory board, aiming to advance NLM-001 in idiopathic pulmonary fibrosis, a disease with high mortality and limited treatment options.

Focus on developing small molecule inhibitors of the Hedgehog (Hh) signaling pathway, with a claimed differentiated pharmacokinetic profile (linear, dose-proportional, rapid absorption/elimination) compared to other Hh inhibitors.

In IPF, Nelum would compete against approved anti-fibrotics (nintedanib, pirfenidone) and a pipeline of novel mechanisms from larger biopharma. In the broader Hh inhibitor class, it competes with drugs like vismodegib and sonidegib (oncology), aiming to differentiate primarily on its pharmacokinetic profile and safety.